---
artifact: strategic-alignment-report
consolidated_draft: cd-001
project: aurelis-alr217-dlbcl-2026
created: 2026-05-02
---

# Strategic Alignment Report

## Scope

Reviewed the consolidated draft `cd-001` against the engagement briefing's three strategic priorities. The Editor's preceding pass at consolidated context is read-only per §6.8, so the consolidated draft is byte-identical to its as-assembled state. The deliverable consolidates three of the five scaffolded pillars (P-01 unmet need, P-04 clinical evidence, P-05 clinical value framework); the remaining two (P-02 disease mechanism, P-03 mechanism of action) are at `narrative-approved` per the roadmap and were not part of this consolidation.

## Briefing Priorities Reviewed

1. **Priority 1.** Differentiate ALR-217 from emerging bispecific antibodies on convenience, sequencing flexibility, and tolerability in older patients.
2. **Priority 2.** Establish ALR-217's optimal positioning in the 3rd-line and beyond setting given the post-CAR-T treatment landscape.
3. **Priority 3.** Communicate the safety profile credibly to community oncologists, including practical management of expected adverse events.

## Findings

### SA-CD1-001

- target: deliverable
- priority_affected: Priority 2
- issue: Strategic Priority 2 — establishing ALR-217's optimal positioning in the 3rd-line and beyond setting given the post-CAR-T treatment landscape — is under-addressed at the deliverable level. Each pillar touches adjacent territory: P-01 establishes the medical-need framing for the post-CAR-T population (SS-01, SS-02); P-04 establishes efficacy and safety in the same population (SS-01, SS-02); P-05 establishes a multi-dimensional value framework (SS-01, SS-02). None of the three pillars synthesizes these inputs into an explicit positioning recommendation for the 3rd-line and beyond setting. A reader of the deliverable can infer the positioning, but the deliverable does not advance it as an explicit claim. Priority 2 calls for *establishing* the positioning, not for assembling the inputs from which it could be derived.
- severity: high
- recommendation: Add a positioning-focused scientific statement to either P-01 (as SS-03 — "ALR-217's positioning in the 3rd-line and beyond setting") or P-05 (as a new SS-03 within the value framework — "Positioning ALR-217 in the post-CAR-T sequencing decision"), with explicit cross-references to P-01.SS-01, P-04.SS-01, P-04.SS-02, and the operational arguments in P-01.SS-02 and P-05.SS-02. Re-consolidate to `cd-002` and re-run `/pilar:run-qc --consolidated`.

### SA-CD1-002

- target: deliverable
- priority_affected: Priority 1
- issue: The bispecific-comparison framing is consistently descriptive (operational and tolerability differentiation) and appropriately avoids cross-trial efficacy comparison given the single-arm evidence base. The framing is well-distributed across P-01.SS-02, P-04.SS-02, and P-05.SS-02, and the lexicon harmonization applied at the consolidated stage (`post-CAR-T`, `older patients`) reinforces the cross-pillar consistency. No issue.
- severity: low
- recommendation: No action. This is a positive finding; the priority is well-addressed.

### SA-CD1-003

- target: P-05
- priority_affected: Priority 3
- issue: Priority 3 (community-oncologist credibility on safety) is addressed in P-04.SS-02 ("operationally important for community oncologists who manage these patients without dedicated infusion infrastructure or on-call neurology consultation") but is not picked up in P-05's value framework. P-05 frames value for academic KOLs, P&T committees, and payers per its Strategic Rationale, but the community-oncologist audience that Priority 3 calls out by name is not given an explicit value-framing thread within the value-framework pillar. This is a balance issue rather than an omission — P-04 carries the audience-specific framing — but the value pillar's structure undersells the operational case from the community-oncologist's perspective.
- severity: medium
- recommendation: In the next consolidation cycle, either expand P-05 to add an explicit community-oncologist framing (e.g. an SS or RS that frames value from the community-treatment perspective specifically) or document in P-05's Scope the deliberate decision to delegate the community-oncologist framing to P-04. Either resolution is acceptable; the current state leaves the framing implicit in a way that may not survive client review.
